Metis is quietly transforming the way blockchain and Web3 applications are built. Unlike the homogeneous competition among other projects, this team has adopted a dual-network strategy—Andromeda handles fundamental security, while Hyperion focuses on execution optimization, supporting parallel transactions and on-chain AI inference. This combination has made Metis an indispensable infrastructure player in the ETH ecosystem.

What’s more interesting is their consideration of developer friendliness. The self-developed SDK significantly reduces the difficulty of developing AI+Web3 applications, meaning more creative projects can go live quickly. The LazAI protocol’s solution to data sovereignty directly addresses the pain points of the current AI economic ecosystem. This business-driven design approach is worth paying attention to.

But Metis’s ambitions are not limited to the chain. In the healthcare field, they are tackling the efficiency challenges of new drug development through AI-driven formulation optimization technology. Nanodelivery technology, combined with the OpenCGT platform, is accelerating the clinical application progress of frontier medical fields like gene therapy. This cross-domain technical output capability demonstrates the team’s deep technical expertise.

In terms of funding trends, continuous support from leading institutions and large-scale financing validate the market’s recognition of its strategic layout. Whether in blockchain infrastructure or AI application layers, Metis is demonstrating what it means to “deploy in multiple points and precisely position.”